Olin:
I read your comments to Rick's proposal with interest. There are good points made on both sides. I would comment on your proposal to identify a small set of elite lines that is acceptable to many programs. I'm not sure it's necessary to transform a set of elite lines. I admit some bias because my material is almost spring anyway. However, I think that a reasonably adapted spring wheat such as Bobwhite is a good vehicle for release and it is not necessary to put the gene into elite lines. Elite lines change over time anyway change over time and the transformation effort would take additional time and resources. Bobwhite can be grown almost anywhere and is particularly amenable to greenhouse crossing since it does not require vernalization. Since the F1 progeny will also not require vernalization, it is easy to make a backcross in the greenhouse before beginning to select for transformed winter types. The KSU wheat germplasm center has been releasing BC1 tauschiis and related material as a means of making new genes available for some time. This works quite well even though the germplasms are generally not adapted. It might be worthwhile to try and identify a hard and a soft wheat, or develop one, that can be easily transformed.
Regards,
Steve Harrison
----------
From: Olin D Anderson oanderson@pw.usda.gov To: wardri@pilot.msu.edu; fhbtalk_mg@msue.msue.msu.edu Subject: Re: scab ideas Date: Saturday, May 09, 1998 2:49 PM
Rick,
But imagine for a moment that the wheat/barley-targeted engineered versions of TRIr
you
are now working with (or PDR5 or anything else)do in fact prove useful
and
warrant inclusion in cultivars. That proof is several years away. If
we
wait for confirmation to initiate plant breeding efforts to deploy
those
constructs, we will have lost several years [because we could start deployment now]. If we start deploying them now and they prove
inadequate,
we will have wasted the breeding resources involved. This represents
two
'errors' or loss scenarios-
- We are cautious and await proof of function, and start deployment
three??
years after the gene was available 2) We proceed with deployment only to learn that the gene fails to meet
our
needs.
To me, the second kind of error is miniscule in cost compared to the
first.
You've correctly pointed out a sticky fundamental strategey question;
i.e.,
how soon to put transgenes into a breeding program? I see it as the type of question that has no fixed answer but is determined on a case by case evaluation of resources, priorities, individual program preferences, etc.
My own predilection is to at least get some indication of resistance
before
recommending inclusion into a breeding program - to avoid wasting effort
on
ineffective transgenes. However, this is really a decision of the
breeding
programs and consideration by the Scab Initiative Steering committee.
Labs
like ours can transform, confirm whether the transgene is present, and continue to characterize the transgenic line, but moving into testing and when to include in breeding programs are decisions others must make (and with whom we would fully cooperate).
exactly how would the step 2 take place? Transform all elite
varieties?
Through sexual hybridization and conventional breeding?
There are still certain cultivars that transform relatively easily (we
still
use Bobwhite) while others are almost totally recalcitrant. What might
be
possible is an identification of a small set of elite lines acceptable to many different programs and which are transformable with reasonable
effort.
This would take some effort and resources to establish. All this assumes the current technology and could change with new advances.
I see the newly available TRIr gene as an opportunity to facilitate maturation of the genetic part of the initiative into a fine-tuned deployment system. I propose we declare TRIr (and other transgenes??)
a
target for development and testing of a gene deployment system. In
some
sense I'm suggesting a 'war game' where we assume TRIr is a useful
gene. It
may turn out to be a dry-run, but we will have addressed in a real
world
manner the logistical and organizational hurdles that are difficult to imagine, let alone conquer. (and of course if TRIr works, not an
entirely
unlikely scenario, we will have achieved our goal of enhancement of
in-farm
resistance levels in the shortest period of time possible).
Viewing the TRIr gene (and possibly a few others) as an experiment in
speed
of deployment certainly has merit - as long as we all understand that any specific gene is likely to fail - that's why we need to try as many as possible. The TRIr gene has the right "feel" of something that could
work,
but we don't want to mislead growers and agencies into thinking it's more of a sure thing than it is. But, I think I agree that the TRIr gene (or some others coming along in different labs) could be used to test
transgene
utilization so we have a clearer idea how all of this will actually work.
Olin Anderson